Paper Details

  1. Home
  2. Paper Details

PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise.

Author: Bou ZeidNaji, YazbeckVictor

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This mini-review revisits the clinical successes, the failures, and the promising aspect of PI3K inhibitors in the treatment of hematologic malignancies. It also presents possible ways that could benefit its successful development.
Paper Details　
Original Abstract of the Article :
Phosphatidylinositol 3-kinases (PI3Ks) are a family of intracellular signal transducer enzymes that can attach a phosphate group to the 3'-hydroxyl of the inositol moiety of membrane-embedded phosphatidylinositol (PI). PI3Ks have been shown to play important roles in cell proliferation, growth, surv...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008402/

データ提供：米国国立医学図書館（NLM）

PI3K Inhibitors: A Double-Edged Sword in Cancer Treatment

The world of cancer research is always on the hunt for new weapons against these formidable foes. This study focuses on PI3K inhibitors, a class of drugs designed to target a specific signaling pathway implicated in various cancers, especially B-cell malignancies. The researchers analyzed the promise and pitfalls of these inhibitors, exploring their potential to effectively treat chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and indolent non-Hodgkin lymphomas (iNHL). This review highlights the complex nature of drug development and the importance of carefully evaluating both efficacy and safety.

Unveiling the Complexities of PI3K Inhibitors

The study reveals a fascinating narrative of hope and caution. While some PI3K inhibitors have shown promising results in initial trials, subsequent studies revealed worrisome trends, including decreased overall survival and increased severe adverse effects. This highlights the need for rigorous research and careful monitoring in the development of new cancer treatments.

Navigating the Landscape of Cancer Treatment

The research emphasizes the importance of considering the multifaceted nature of cancer treatment. It's essential to weigh the potential benefits of new therapies against their potential risks. Future research should focus on optimizing PI3K inhibitors to improve their safety profiles, potentially leading to more effective treatments with fewer side effects.

Dr.Camel's Conclusion

This review underscores the importance of cautious optimism in cancer drug development. The journey of PI3K inhibitors serves as a reminder that even promising therapies can have unforeseen consequences. As scientists and clinicians, we must remain vigilant in our pursuit of effective cancer treatments while ensuring patient safety.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-03-17
Further Info :

Pubmed ID

36919100

DOI: Digital Object Identifier

PMC10008402

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.